Abstract:Clinical and preclinical studies have implicated glial anomalies in major depression. Conversely, evidence suggests that the activity of antidepressant drugs is based, at least in part, on their ability to stimulate density and/or activity of astrocytes, a major glial cell population. Despite this recent evidence, little is known about the mechanism(s) by which astrocytes regulate emotionality. Glial cells communicate with each other through gap junction channels (GJCs), while they can also directly interact with neurons by releasing gliotransmitters in the extracellular compartment via an hemichannels (HCs)-dependent process. Both GJCs and HCs are formed by two main protein subunits: connexins (Cx) 30 and 43 (Cx30 and Cx43). Here we investigate the role of hippocampal Cx43 in the regulation of depression-like symptoms using genetic and pharmacological approaches. The first aim of this study was to evaluate the impact of the constitutive knock-down of Cx43 on a set of behaviors known to be affected in depression. Conversely, the expression of Cx43 was assessed in the hippocampus of mice subjected to prolonged corticosterone (CORT) exposure, given either alone or in combination with an antidepressant drug, the selective serotonin reuptake inhibitor fluoxetine. Our results indicate that the constitutive deficiency of Cx43 resulted in the expression of some characteristic hallmarks of antidepressant-/anxiolytic-like behavioral activities along with an improvement of cognitive performances. Moreover, in a new cohort of wild-type mice, we showed that CORT exposure elicited anxiety and depression-like abnormalities that were reversed by chronic administration of fluoxetine. Remarkably, CORT also increased hippocampal amounts of phosphorylated form of Cx43 whereas fluoxetine treatment normalized this parameter. From these results, we envision that antidepressant drugs may exert their therapeutic activity by decreasing the expression and/or activity of Cx43 resulting from a lower level of phosphorylation in the hippocampus.

Gap Junction Dysfunction in the Prefrontal Cortex Induces Depressive-Like Behaviors in Rats

The Protective Role Of Neuregulin1-Erbb4 Signaling In A Chronic Social Defeat Stress Model

Gap junction channels as potential targets for the treatment of major depressive disorder

Gap junction is essential for the antidepressant effects of fluoxetine

Astroglial Connexin 43-Mediated Gap Junctions and Hemichannels: Potential Antidepressant Mechanisms and the Link to Neuroinflammation

Ginsenoside Rg1-induced antidepressant effects involve the protection of astrocyte gap junctions within the prefrontal cortex

Astroglial Connexins Inactivation Increases Relapse of Depressive-like Phenotype after Antidepressant Withdrawal

Glial pathology in an animal model of depression: reversal of stress-induced cellular, metabolic and behavioral deficits by the glutamate-modulating drug riluzole

The protective effect of ginsenoside Rg1 on depression may benefit from the gap junction function in hippocampal astrocytes

[Gap junctions: A new therapeutic target in major depressive disorder?]

Exercise Alleviates CUS-Induced Depressive-Like Behaviors by Modulating Paracellular and Transcellular Permeability of the Blood-Brain Barrier in the Prefrontal Cortex

Deficiency of astrocyte CysLT 1 R ameliorates depression-like behaviors in mice by modulating glutamate synaptic transmission

Attenuated Levels of Hippocampal Connexin 43 and its Phosphorylation Correlate with Antidepressant- and Anxiolytic-Like Activities in Mice

Alteration in NMDAR subunits in different brain regions of chronic unpredictable mild stress (CUMS) rat model

Targeting Gap Junctions: New Insights into the Treatment of Major Depressive Disorder

Novel antidepressant mechanism of hypericin: Role of connexin 43-based gap junctions

Stress-induced myelin damage in the hippocampal formation in a rat model of depression

Connexin 43: An Interface Connecting Neuroinflammation to Depression

Prefrontal cortex astrocytes in major depressive disorder: exploring pathogenic mechanisms and potential therapeutic targets

Regulation of depression-related behaviors by GABAergic neurons in the lateral septum through periaqueductal gray neuronal projections